1 – 10 of 33
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
- Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
- 2019
- Direct comparison of two extended-half-life recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
- 2017
-
Comparative burden of arthropathy in mild haemophilia : a register-based study in Sweden
Osooli, M LU
; Lövdahl, S
LU
; Steen Carlsson, K
LU
; Knobe, K
LU
; Baghaei, F.
; Holmström, M
; Astermark, J
LU
and Berntorp, E
LU
(2017)
In Haemophilia
23(2).
p.79-86
Mark
- Effect of late prophylaxis in hemophilia on joint status : A randomized trial
- Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients : Results of the INSIGHT case-control study
- 2016
- Aspects of prophylactic treatment of hemophilia
- Does the intensity and quality of treatment and not only the factor VIII level influence global hemostasis in patients with hemophilia A?
- Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
- 2014
-
Factor VIII therapy for hemophilia A: current and future issues
Aledort, Louis ; Ljung, Rolf LU
; Mann, Kenneth
and Pipe, Steven
(2014)
In Expert Review of Hematology
7(3).
p.373-385
Mark
- The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A